Skip to main content

Advertisement

Log in

Optimal image guidance for tumor biopsy in non-small-cell lung cancer

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, et al. New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04500-7.

  2. Kasahara N, Kaira K, Bao P, Higuchi T, Arisaka Y, Erkhem-Ochir B, et al. Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. Lung Cancer. 2018;119:71–7. https://doi.org/10.1016/j.lungcan.2018.03.001.

    Article  PubMed  Google Scholar 

  3. Kaira K, Shimizu K, Kitahara S, Yajima T, Atsumi J, Kosaka T, et al. 2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. Eur J Cancer. 2018;101:181–90. https://doi.org/10.1016/j.ejca.2018.06.022.

    Article  CAS  PubMed  Google Scholar 

  4. Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43(11):1954–61. https://doi.org/10.1007/s00259-016-3425-2.

    Article  CAS  PubMed  Google Scholar 

  5. Levy EB, Fiel MI, Hamilton SR, Kleiner DE, McCall SJ, Schirmacher P, et al. State of the art: toward improving outcomes of lung and liver tumor biopsies in clinical trials-a multidisciplinary approach. J Clin Oncol. 2020:JCO1902322. https://doi.org/10.1200/JCO.19.02322.

  6. Purandare NC, Kulkarni AV, Kulkarni SS, Roy D, Agrawal A, Shah S, et al. 18F-FDG PET/CT-directed biopsy: does it offer incremental benefit? Nucl Med Commun. 2013;34(3):203–10. https://doi.org/10.1097/MNM.0b013e32835c5a57.

    Article  CAS  PubMed  Google Scholar 

  7. Cho A, Hur J, Kang WJ, Cho HJ, Lee JH, Yun M, et al. Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. Eur Radiol. 2011;21(5):1077–87. https://doi.org/10.1007/s00330-010-2006-1.

    Article  PubMed  Google Scholar 

  8. Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol. 2016;27(1):147–53. https://doi.org/10.1093/annonc/mdv489.

    Article  CAS  PubMed  Google Scholar 

  9. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274–93. https://doi.org/10.1016/j.cell.2012.03.017.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Evangelista L. The prediction of response to immunotherapy in non-small cell lung cancer patients by 18F-FDG PET/CT. J Thorac Dis. 2019;11(11):E221–E3. https://doi.org/10.21037/jtd.2019.10.19.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Chen L, Zhou Y, Tang X, Yang C, Tian Y, Xie R, et al. EGFR mutation decreases FDG uptake in non-small cell lung cancer via the NOX4/ROS/GLUT1 axis. Int J Oncol. 2019;54(1):370–80. https://doi.org/10.3892/ijo.2018.4626.

    Article  CAS  PubMed  Google Scholar 

  12. Lv Z, Fan J, Xu J, Wu F, Huang Q, Guo M, et al. Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients. Eur J Nucl Med Mol Imaging. 2018;45(5):735–50. https://doi.org/10.1007/s00259-017-3885-z.

    Article  CAS  PubMed  Google Scholar 

  13. Sun X, Xiao Z, Chen G, Han Z, Liu Y, Zhang C, et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl Med. 2018;10(431). https://doi.org/10.1126/scitranslmed.aan8840.

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Haojun Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not describe any studies with human participants performed by any of the authors.

Additional information

This article is part of the Topical Collection on Letter to the Editor

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, L., Lin, Q. & Chen, H. Optimal image guidance for tumor biopsy in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 47, 2739–2740 (2020). https://doi.org/10.1007/s00259-020-04835-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-04835-6

Navigation